Choosing anticancer drug targets in the postgenomic era

J Clin Invest. 1999 Dec;104(11):1503-6. doi: 10.1172/JCI8888.
No abstract available

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Cell Division / drug effects
  • Cell Division / genetics
  • Drug Design
  • Gene Targeting
  • Genes, Tumor Suppressor
  • Humans
  • Mutation
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / metabolism
  • Retinoblastoma Protein / genetics
  • Retinoblastoma Protein / metabolism

Substances

  • Antineoplastic Agents
  • Proto-Oncogene Proteins
  • Retinoblastoma Protein